FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	S IN BENEFICIA	AL OWNERSHI	Ρ

OIVID APPROVAL								
OMB Number:	3235-0287							
Estimated average h	nurden							

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Fair Richard A.			<u>P</u>	2. Issuer Name and Ticker or Trading Symbol BELLICUM PHARMACEUTICALS, INC BLCM					C [Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) 2130 WE STE.800	,	irst) OMBE BLVD.	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 07/02/2018						X Officer (give title Other (specify below) President and CEO					
(Street) HOUST(X tate)	77030 (Zip)	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	Y Form fil Form fil	ridual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Da			Transaction ate Ionth/Day/	Execu h/Day/Year) if any		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.			Beneficia Owned Fo	s Form ally (D) o ollowing (I) (In	rm: Direct I or Indirect I (Instr. 4) (7. Nature of ndirect Beneficial Ownership		
								Code V	Amount	(A) o (D)	r Price	Reported Transacti (Instr. 3 a	on(s)		Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3) 2. Conversio or Exercis Price of Derivative Security		cise (Month/Day/Year) if any f ive (Month/Day/		4. Transaction Code (Instr. r) 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Stock Option (right to buy)	\$7.72	07/02/2018		A		225,000		(1)	07/01/2028	Common Stock	225,000	\$0	225,000	D		

Explanation of Responses:

1. 25% of the shares subject to the stock option vest and become exercisable on January 2, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments

Remarks:

/s/ Alan Musso, Attorney-in-07/05/2018 **Fact**

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.